A pilot study of irradiated HLA [human leukocyte antigen] partially matched allogeneic related donor lymphocytes in conjunction with rituximab for selected patients with CD20 + malignancies.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Rituximab (Primary)
- Indications Lymphoproliferative disorders
- Focus Adverse reactions; Therapeutic Use
- 17 Sep 2013 Biomarkers information updated
- 15 Dec 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 17 Nov 2009 Actual end date (Feb 2008) added as reported by ClinicalTrials.gov.